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Abstract
The stagnant mortality rates for metastatic urothelial cancer (UC) have provoked efforts to ﬁnd novel treatments. To test the utility of
the extirpative surgery for primary tumor as an option for these patients, we investigated the perioperative and oncologic outcomes of
surgery for primary tumors in metastatic UC patients.
We reviewed the medical records of 130 metastatic UC patients (bladder: 88, upper tract UC: 42) at diagnosis from November
2005 to November 2016. A total of 56 patients (surgery group) underwent chemotherapy with extirpative surgery for the primary
tumor, and 74 patients (non-surgery group) received chemotherapy. We evaluated perioperative outcomes, cancer-speciﬁc survival
(CSS), and overall survival (OS) using Kaplan-Meier methods and factors related to OS and CSS using Cox regression models.
Surgery group showed similar perioperative outcome and postoperative complications to those previously reported in UC patients
without metastasis, and fewer urinary complications than non-surgery group. Surgery group showed better oncological outcomes
than non-surgery group for median CSS (16.0 vs 10.0 months, P=0.014) and median OS (14.0 vs 9.0 months, P=0.043).
Multivariate analysis showed Eastern Cooperative Oncology Group performance status and metastasis to liver as signiﬁcant
predictors of CSS and OS. Surgery was not related with OS, but a signiﬁcant predictor of CSS.
Extirpative surgery for primary tumor in metastatic UC can be feasible and it might have survival beneﬁts, especially those patients
with a tolerable general condition and no liver metastasis. In addition, LT reduces the possibility of a surgical procedure towing to
urinary complications.
Abbreviations: BCa = bladder cancer, BMI = body mass index, CSS = cancer-speciﬁc survival, ECOG = Eastern Cooperative
Oncology Group, LN = lymph node, LT = local treatment, OS = overall survival, UC = urothelial carcinoma, UTUC = upper tract
urothelial carcinoma.
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11. Introduction
Bladder cancer (BCa) is the most common malignancy in the
urinary tract and ninth most common cancer worldwide.[1] In
Korea, 3762 patients were newly diagnosed with and 1280 died
from BCa in 2013.[2] In contrast, upper tract urothelial
carcinoma (UTUC) is a relatively rare malignancy; for example,
the incidence of UTUC has been reported as 2 per 100,000
persons in the United States.[3] Within these groups, the disease
in 5% to 15% of patients with BCa[4] and 8% to 30% of
patients with UTUC[3,5] had metastasized at the time of
diagnosis. Although studies have identiﬁed several novel
therapeutic targets for the development of systemic therapies[6]
and immune checkpoint inhibitors,[7] there has been little
improvement in the mortality rates of metastatic disease since
the introduction of cisplatin-based combination chemotherapy
>20 years ago.[8]
There are many studies that indicate cytoreductive surgery for
primary tumor improves survival in some situations of metastatic
carcinoma, such as renal cell carcinoma, colon cancer, and
ovarian cancer.[9–11] Also, although androgen deprivation
therapy is regarded as the standard treatment in patients with
metastatic prostate cancer, recent studies indicate that local
treatment (LT) such as prostatectomy or radiotherapy is related
to increased overall survival (OS) in metastatic prostate cancer
patients.[12]
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cancers, there are few studies about LT in cases of metastatic
urothelial carcinoma (UC). Historically, combination chemo-
therapy has been the standard treatment option for metastatic
UC,[13] and surgery or radiotherapy has been considered only
with palliative intention to control the intractable symptoms
owing to disease progression. However, the median survival is
reported as only approximately 14 months, although cisplatin-
based combination chemotherapy has improved the survival of
patients with metastatic UC.[14,15]
In this situation, some recent population studies have evaluated
whether LT had beneﬁt for metastatic BCa and reported that
high-intensity LT (radical cystectomy of bladder or treatments
with radiotherapy dose of ≥50 Gy) improves OS in patients with
metastatic BCa.[16,17] Considering these reports, our aim was to
assess the feasibility and impact of extirpative surgery for primary
tumor on OS and cancer-speciﬁc survival (CSS) in patients with
metastatic UC. Moreover, we evaluated whether the surgery for
primary tumor could reduce urinary tract complications caused
by disease progression (eg, hematuria, obstruction, or urinary
retention[18]).2. Materials and methods
2.1. Patient selection
We reviewed the records of 135 patients who were initially
diagnosed with various forms of metastatic UC in our institution
from November 2005 to November 2016. All patients were
histologically diagnosed with UC by biopsy or operation (eg,
transurethral resection of bladder tumor, cystoscopic bladder
biopsy, or ureteroscopic biopsy) and they had distant metastasis
in preoperative imaging such as abdomino-pelvic computed
tomography (CT), chest CT, bone scan, or positron emission
tomography. Patients with only regional lymph node (LN)
involvement without distant metastasis were excluded. Two
patients with brain metastasis or carcinomatosis and 3 patients
with unavailable clinical information were excluded. Of the 130
patients who were included in the analysis (bladder: 88, upper
tract UC: 42), 56 underwent chemotherapy with extirpative
surgery for primary tumor. The other 74 patients who received
chemotherapy were assigned to the non-surgery group. The
decision as to treatment methodwas left to the physician’s clinical
judgement after discussion with the patient regarding the
probable beneﬁts and adverse effects of each treatment.
The TNM stage was determined according to the guidelines in
the 8th edition of the American Joint Committee on Cancer
Staging Manual.[19] Other clinical characteristics, including sex,
age, body mass index (BMI), Eastern Cooperative Oncology
Group (ECOG) performance status, smoking status, and urinary
complications, were investigated by reviewing medical records.
Urinary complications were deﬁned as problems in the urinary
tract owing to disease progression, and only the cases that
required surgical intervention were investigated for our analysis.2.2. Treatments and follow-up
Patients in the surgery group underwent chemotherapy after
extirpative surgery. Chemotherapy regimens were either gemci-
tabine and cisplatin (or carboplatin in patients unﬁt for cisplatin)
or MVAC (methotrexate, vinblastine, doxorubicin, and cisplat-
in). The period of the chemotherapy and regimen changes were2made according to the treatment response and performance
status of the patients and were left to the judgment of the
clinicians.
Information on survival status and cause of death was obtained
from the National Cancer Registry Database and our institution-
al electronic medical records. The OS was deﬁned as the period
from the ﬁrst diagnosis of UC to the date of all-cause death. CSS
was determined by the date of cancer-speciﬁc death or censoring.2.3. Statistical analysis
Patient clinical characteristics between the 2 study groups were
compared using the Mann–Whitney U test for continuous data
and x2 test for dichotomous variables. Categorical variables were
described with frequency and percentages, and continuous
variables were described with medians and interquartile range
(IQR). Kaplan-Meier methods with a log-rank test were used to
evaluate OS and CSS between 2 groups. Factors related to CSS
were determined using Cox proportional hazard models.
Variables for multivariate analysis were selected by univariate
analyses. Comparisons with signiﬁcance levels of P< .05 were
considered statistically signiﬁcant. All statistical analyses were
performed using SPSS software, version 23.0 (IBM Corp.,
Armonk, NY). All statistical tests were 2-tailed, and a P value
<.05 was considered statistically signiﬁcant.2.4. Good clinical practice protocols
This study was performed in agreement with the applicable laws
and regulations, good clinical practices, and ethical principles
described in the Declaration of Helsinki. This study protocol was
approved by the institutional review board of the hospital
(approval number: 4–2018–0214).3. Results
The demographic characteristics of all the patients are shown in
Table 1. There were more patients with liver metastasis in the
non-surgery than in the surgery group (17.6% vs 3.6%,
respectively; P= .013). And patients with UTUC were more
likely to receive surgery than those with BCa (57.1% vs 36.4%,
respectively; P= .025). Moreover, patients who had to receive
surgical intervention because of urinary tract complications were
more prevalent in the non-surgery group than the surgery group
(27.0% vs 1.8%, respectively; P< .001).
Table 2 shows the perioperative outcomes and pathological
characteristics of 56 patients with metastatic UC treated with
surgery for primary tumor. The median (interquartile range
[IQR]) operating time was 272 (196–378) minutes and 221 (171–
258) minutes in radical cystectomy and nephroureterectomy
group, respectively. The median estimated blood loss was 850
(600–1580) mL and 400 (205–875) mL, the median (IQR) length
of hospitalization was 13 (10–17) days and 7 (5–11) days in each
group, respectively. Sixteen patients (50.0%) of radical cystec-
tomy group and 5 patients (20.8%) of nephroureterectomy group
received blood transfusion. Two patients (6.2%) and 1 patient
(3.1%) in radical cystectomy group experienced grade 3 and 4
postoperative complications by 30 days, respectively. Two
patients (6.2%) underwent wound closure owing to wound
dehiscence, 1 (3.1%) needed general anesthesia, and 1 patient
received had unplanned intensive care unit admission because of
hemodynamic instability.
Table 1
Patient characteristics.
Total Non-surgery Surgery
Characteristics 130 74 56 P
Sex (%) .383
Male 109 (83.8%) 64 (86.5%) 45 (80.4%)
Female 21 (16.2%) 10 (13.5%) 11 (19.6%)
Age, median (IQR), y 64 (58–70) 66 (58–73) 63 (57–68) .11
BMI, median (IQR), kg/m2 23.02
(21.63–24.93)
23.07
(21.71–25.31)
23.00
(21.63–24.79)
.691
ECOG .038
1 87 (66.9%) 44 (59.5%) 43 (76.8%)
≥2 43 (33.1%) 30 (40.5%) 13 (23.2%)
Smoking .026
Nonsmoker 53 (40.8%) 24 (32.4%) 29 (51.8%)
Current or former smoker 77 (60.2%) 50 (67.6%) 27 (48.2%)
Primary tumor .025
Bladder 88 (67.7%) 56 (75.7%) 32 (57.1%)
Ureter and renal pelvis 42 (32.3%) 18 (24.3%) 24 (42.9%)
Clinical T stage .076
cT2 20 (15.4%) 15 (20.3%) 5 (8.9%)
≥cT3 110 (84.6%) 59 (79.7%) 51 (91.1%)
Clinical N stage .043
N0 35 (26.9%) 25 (33.8%) 10 (17.9%)
≥cN1 95 (73.1%) 49 (66.2%) 46 (82.1%)
LN involved 59 (45.4%) 39 (52.7%) 20 (35.7%) .054
Lung involved 50 (38.5%) 24 (32.4%) 26 (46.4%) .104
Bone involved 52 (40.0%) 33 (44.6%) 19 (33.9%) .219
Liver involved 15 (11.5%) 13 (17.6%) 2 (3.6%) .013
Visceral involved 98 (75.4%) 54 (73.0%) 44 (78.6%) .463
Tumor variant 14 (10.8%) 7 (9.5%) 7 (12.5%) .58
BMI=body mass index, ECOG=Eastern Cooperative Oncology Group, IQR= inter-quartile range,
LN= lymph node.
Table 3
Urinary tract complications requiring surgical procedure.
Non-surgery Surgery P
Complications 20 (27.0%) 1 (1.8%) <.001
Hematuria
Cystoscopic cauterization 4 (5.4%) 0 (0.0%)
Obstructive uropathy
Double J stent indwelling 8 (10.8%) 0 (0.0%)
PCN 6 (8.1%) 1 (1.8%)
Urinary retention
Suprapubic cystostomy 2 (2.7%) 0 (0.0%)
PCN=percutaneous nephrostomy.
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cations in each group are shown in Table 3. Twenty patients in
the non-surgery group needed surgical intervention because of
intractable hematuria, ureteral obstruction, or bladder outletTable 2
Perioperative and pathological characteristics of patients with
metastatic urothelial carcinoma treated with surgery for primary
tumor.
Radical
cystectomy
(n=32)
Nephroureterectomy
(n=24)
Median operating time (IQR), min 272 (196–378) 221 (171–258)
Median estimated blood loss (IQR), mL 850 (600–1580) 400 (205–875)
Blood transfusion (%) 16 (50.0%) 5 (20.8%)
Median hospital stays (IQR), days 13 (10–17) 7 (5–11)
Postoperative complications, n (%)
∗
1 7 (21.9%) 2 (8.3%)
2 4 (12.5%) 2 (8.3%)
3a 1 (3.1%) 0 (0.0%)
3b 1 (3.1%) 0 (0.0%)
4 1 (3.1%) 0 (0.0%)
5 0 (0.0%) 0 (0.0%)
Type of urinary diversion, n (%)
Ureterocutaneostomy 3 (9.4%)
ICUD 28 (87.5%)
Neobladder 1 (3.1%)
Pathologic T stage, n (%)
2 5 (15.6%) 0 (0.0%)
3 8 (25.0%) 7 (29.2%)
4 19 (59.4%) 17 (70.8%)
Pathologic N stage, n (%)
pN0 6 (18.7%) 1 (4.2%)
pN1 20 (62.5%) 1 (4.2%)
pN2 3 (9.4%) 5 (20.8%)
pNx 3 (9.4%) 17 (70.8%)
Median removed LN (IQR)† 17 (9–25) 5.5 (3.5–8)
ICUD= ileal conduit urinary diversion, IQR= interquartile range, LN= lymph node.
∗
Complications according to Clavien–Dindo classiﬁcation system.
† Data of patients who underwent lymph node dissection.
3obstruction. In contrast, only 1 patient needed surgical
intervention for ureteral obstruction in the surgery group.
At a median follow-up of 13 months (IQR=6–22 months),
121 patients died (112 of UC). Kaplan–Meier curves (Fig. 1)
showed that median CSS was signiﬁcantly longer in surgery
group (16.0 [IQR, 10.0–27.0] vs 10.0 [IQR, 4.0–21.0] months,
P= .014, respectively). Andmedian OSwas also longer in surgery
group versus non-surgery group (14.0 [IQR, 10.0–25.0] vs 9.0
[IQR, 4.0–21.0] months; P= .043, respectively). Multivariate
analysis demonstrated that higher ECOG (hazard ratio [HR]=
2.001, 95% conﬁdence interval [CI]=1.313–3.050, P= .001)
and metastasis to liver (HR=2.147, 95% CI=1.210–3.807,
P= .009) were associated with worse CSS. Surgery (HR=0.663,
95% CI=0.449–0.980, P= .039) seemed to improve CSS in
patients with metastatic UC (Table 4). In the context of OS,
multivariate analysis revealed that higher ECOG (hazard ratio
[HR]=2.129, 95% conﬁdence interval [CI]=1.423–3.185,
P< .001) and liver metastasis (HR=2.161, 95% CI=1.227–
3.807, P= .008) were associated with worse OS. However,
surgery (HR=0.723, 95% CI=0.500–1.055, P= .093) was not
related to OS (Table 5).
Considering the effect of metastatic lesions on survival, only
liver involvement was conﬁrmed to be related to CSS (HR=
2.147, 95% CI=1.210–3.807, P= .009) and OS (HR=2.161,
95% CI=1.227–3.807, P= .008). Interestingly, visceral metas-
tasis was not associated with CSS (HR=0.972, 95% CI=0.964–
3.086, P= .066) or OS (HR=0.1.023, 95% CI=0.892–1.541,
P= .915).4. Discussion
The EAU guideline on metastatic UC recommends the use of
cisplatin-containing combination chemotherapy, such as gemci-
tabine and cisplatin or MVAC (methotrexate, vinblastine,
doxorubicin, cisplatin).[13,19] The initial response rate of
chemotherapy is 50% to 60%, complete responses are reported
as 20% in metastatic BCa, and 5-year OS rate is <15%.[15,20] In
cases of UTUC, the initial complete response rate of combination
chemotherapy has been reported as up to 30%, but almost all
patients experience relapse or disease progression.[21] Although
novel immune therapy such as atezolizumab has been used to
manage advanced or metastatic UC,[22,23] the survival rate of
patients with metastatic UC has not been improved dramatically
since the early 1990s when cisplatin-containing combination
chemotherapy was introduced.[13] In light of these reports, it may
be necessary to reconsider the role of LT on primary tumors in the
patients with metastatic UC.
Figure 1. Kaplan-Meier curve of overall survival rates and cancer-speciﬁc survival in patients who received extirpative surgery versus systemic chemotherapy for
metastatic urothelial carcinoma.
Table 4
Univariate and multivariate analysis of factors associated with cancer-speciﬁc survival.
Univariate analysis Multivariate analysis
Variables HR (95% CI) P HR (95% CI) P
Sex .579
Male 1 (Ref)
Female 1.154 (0.696–1.913)
Age 1.006 (0.985–1.026) .593
BMI 0.942 (0.887–1.000) .049 0.951 (0.892–1.013) .116
ECOG <.001 .001
1 1 (Ref) 1 (Ref)
≥2 2.164 (1.438–3.256) 2.001 (1.313–3.050)
Smoking .63
Nonsmoker 1 (Ref)
Current or former smoker 1.098 (0.750–1.608)
Clinical T stage .273
cT2 1 (Ref)
≥cT3 0.754 (0.454–1.250)
Clinical N stage .242
N0 1 (Ref)
≥cN1 0.766 (0.491–1.197)
Extirpative surgery .017 .039
No 1 (Ref) 1 (Ref)
Yes 0.630 (0.430–0.921) 0.663 (0.449–0.980)
LN involved .802
No 1 (Ref)
Yes 0.953 (0.656–1.385)
Lung involved .582
No 1 (Ref)
Yes 1.113 (0.760–1.632)
Bone involved .452
No 1 (Ref)
Yes 0.862 (0.584–1.270)
Liver involved <.001 .009
No 1 (Ref) 1 (Ref)
(continued )
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Table 4
(continued).
Univariate analysis Multivariate analysis
Variables HR (95% CI) P HR (95% CI) P
Yes 2.824 (1.619–4.923) 2.147 (1.210–3.807)
Visceral involved .894
No 1 (Ref)
Yes 0.972 (0.639–1.479)
Tumor variant .066
No 1 (Ref)
Yes 1.725 (0.964–3.086)
BMI=body mass index, CI= conﬁdential interval, ECOG=Eastern Cooperative Oncology Group, HR=hazard ratio, LN= lymph node.
Table 5
Univariate and multivariate analysis of factors associated with overall survival.
Univariate analysis Multivariate analysis
Variables HR (95% CI) P HR (95% CI) P
Sex .579
Male 1 (Ref)
Female 1.154 (0.696–1.913)
Age 1.009 (0.989–1.030) .359
BMI 0.939 (0.886–0.994) .032 0.952 (0.897–1.011) .109
ECOG <.001 <.001
1 1 (Ref) 1 (Ref)
≥2 2.304 (1.556–3.412) 2.129 (1.423–3.185)
Smoking .534
Nonsmoker 1 (Ref)
Current or former smoker 1.124 (0.778–1.624)
Clinical T stage .493
cT2 1 (Ref)
≥cT3 0.839 (0.507–1.387)
Clinical N stage .365
N0 1 (Ref)
≥cN1 1.215 (0.798–1.849)
Extirpative surgery .05 .093
No 1 (Ref) 1 (Ref)
Yes 0.694 (0.482–0.999) 0.723 (0.500–1.055)
LN involved .549
No 1 (Ref)
Yes 0.895 (0.623–1.286)
Lung involved .391
No 1 (Ref)
Yes 1.174 (0.814–1.692)
Bone involved .562
No 1 (Ref)
Yes 0.896 (0.617–1.300)
Liver involved .001 .008
No 1 (Ref) 1 (Ref)
Yes 2.632 (1.513–4.577) 2.161 (1.227–3.807)
Visceral involved .915
No 1 (Ref)
Yes 1.023 (0.679–1.541)
Tumor variant .116
No 1 (Ref)
Yes 1.591 (0.892–2.838)
BMI=body mass index, CI= conﬁdential interval, ECOG=Eastern Cooperative Oncology Group, HR=hazard ratio, LN= lymph node.
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primary tumors in patients with metastatic UC. Recently, Seisen
et al[16] reported the outcome of high-intensity LT (radical
cystectomy or radiotherapy with >50 Gy) on the bladder in5patients with metastatic BCa. The study population and clinical
information were collected from the National Cancer Database
(NCDB) registry, and inverse probability of treatment weighting
was used for balancing covariates between 2 groups. The results
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LT group than the conservative LT group (14.92 vs 9.95 months,
respectively; P< .001). Multivariate analysis also demonstrated
high-intensity LT was associated with better OS (HR=0.56,
P< .001). Given the non-negligible morbidity associated with
high-intensity LT, Vetterlein et al[17] tried to identify patients who
might beneﬁt the most from this treatment. Using the same
NCDB registry, they showed that high-intensity LT provides an
OS beneﬁt, regardless of patient and tumor characteristics, in
patients with metastatic, histologically pure UC of the bladder.
Using the Japanese Urologic Association database registry,
Inokuchi et al[24] reported the survival beneﬁt of multimodal
treatment in patients with metastatic UTUC. The group that
underwent nephroureterectomy with chemotherapy had a
signiﬁcantly longer median OS than the groups that had
supportive care, surgery alone, or chemotherapy alone (25.8
months vs 4.3 months vs 7.3 months vs 3.1 months, respectively;
P< .001). The Cox proportional hazards regressionmodel results
in the Inokuchi et al’s study also showed that multimodal
treatment was associated with better prognosis than supportive
care, chemotherapy alone, or surgery alone (HR=0.32, P
= .001). These results suggest that LT may improve survival in
patients with metastatic UTUC. However, because patients who
received supportive care alone were included in the comparison
groups, it is difﬁcult to conclusively assess the role of LT.
In our study, Kaplan-Meier curve results show that patients
who underwent surgery for primary tumor had better OS.
However, unlike the studies mentioned above, multivariate
analysis demonstrated that surgerywas not a signiﬁcant predictor
of OS. Rather, our study results suggest that surgery might
improve CSS in patients with metastatic UC. And our results
suggest that radical cystectomy and nephroureterectomy can be
feasible for patients with metastatic UC, because not only
perioperative outcomes including operative time, estimated
blood loss, and transfusion rate but also postoperative
complication rate of our study were similar to those previously
reported for radical cystectomy or nephroureterectomy for
standard indications in the previous study.[25,26]
Moreover, we investigated whether surgery for primary tumor
affects the incidence of urinary tract complications and showed
that the surgery group had a lower rate of urinary tract
complications that required surgical intervention during follow-
up. In the non-surgery group, 27.0% of the patients had to
receive surgical intervention owing to urinary tract complica-
tions, whereas only 1.7% of patients in the surgery group
underwent percutaneous nephrostomy owing to ureteral ob-
struction.
Previous studies concerned with oncologic outcome or
prognostic factors of metastatic UC reported visceral metastasis
as a signiﬁcant predictor for survival. Bajorin et al[20] reported the
median survival of patients with visceral metastasis was 11.1
months and without visceral metastasis was 22.3 months
(P= .0001). They also showed that liver (9.87 vs 15.45 months,
P= .0001) or lung metastasis (11.4 vs 15.6 months, P= .024) was
related with poorer OS. Taguchi et al[27] also reported visceral
metastasis was associated with poorer OS (HR=1.424, 95%
CI=1.027–1.981, P= .034). However, our study showed only
liver metastasis was associated with poorer CSS and OS.
Involvement of distant LN, bone, and visceral organs (including
liver, lung, and adrenal gland) did not affect either CSS or OS.
Previous studies included patients with regional LN metastasis
only (N+M0); thus, patients without distant metastasis were6included as a comparison target of patients with visceral
metastasis. However, our study excluded regional LN involve-
ment without distant metastasis, and this difference appears to
have produced different results.
Our study has some limitations. First, it is retrospective study
from a single institution, and selection bias may be reﬂected in our
results. Furthermore, we cannot control clinical variables that
could affect survival, such as sex, age, BMI, smoking status,
clinical TNM stage, and metastatic lesions. Especially, factors
such as ECOG and liver metastasis, which seem to be associated
with oncologic outcome, showed signiﬁcant differences between
the 2 groups. So, we tried to adjust signiﬁcant heterogeneity using
propensity score matching, but we could n’t. Because the number
of patients included in our study was too small, and many
patients were excluded from matching, matched cohort did not
seem to reﬂect the characteristics of the entire cohort. If we
included patients with only regional LN without distant
metastasis or who had progressed to metastatic UC from initially
localized UC, more patients would have been included in our
study. However, there may be different tumor features between
de novo metastatic disease and disease progressed to metastatic
status compared with initially localized UC. Hence, our setting
seems to be more homogeneous in the characteristics of the
patient group. And previous studies have included not only
radical cystectomy but also radiotherapy >50 Gy in high-
intensity LT for metastatic BCa.[16,17] So, it is needed to evaluate
whether radiotherapy can improve survival outcome in further
study. There are other limitations in the analysis of complica-
tions. We found surgery for primary tumor may reduce the
probability of urinary tract complications during follow-up.
However, we did not evaluate the inconvenience associated with
surgery. Some complications after radical cystectomymay be life-
threatening, and 1 study reported that the 30-day mortality after
radical cystectomy was 1.5%.[28] Moreover, radical cystectomy
should be performed with diversion of the urinary tract. Ileal
conduit urinary diversion or ureterocutaneostomy also can be
factors associated with poor quality of life (QOL). Therefore,
there should be further studies evaluating effect of surgery for
primary tumor on QOL using questionnaires like the Functional
Assessment of Cancer Therapy: Bladder Cancer, among
others.[29,30]
Our results suggest that extirpative surgery for primary
tumor in metastatic UC is feasible, and it may improve CSS
and prevent urinary tract complications owing to disease
progression and reduce probability for surgical intervention.
Large, prospective, multicenter studies are needed to conﬁrm
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